Tourmaline Bio Inc. (TRML) - Total Assets
Based on the latest financial reports, Tourmaline Bio Inc. (TRML) holds total assets worth $269.30 Million USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See TRML total equity for net asset value and shareholders' equity analysis.
Tourmaline Bio Inc. - Total Assets Trend (2019–2024)
This chart illustrates how Tourmaline Bio Inc.'s total assets have evolved over time, based on quarterly financial data.
Tourmaline Bio Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Tourmaline Bio Inc.'s total assets of $269.30 Million consist of 87.0% current assets and 13.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 9.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Tourmaline Bio Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see TRML market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tourmaline Bio Inc.'s current assets represent 87.0% of total assets in 2024, a decrease from 97.3% in 2019.
- Cash Position: Cash and equivalents constituted 9.9% of total assets in 2024, down from 92.9% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Tourmaline Bio Inc. Competitors by Total Assets
Key competitors of Tourmaline Bio Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Tourmaline Bio Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 24.68 | 46.87 | 44.29 |
| Quick Ratio | 24.68 | 46.87 | 44.29 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $239.01 Million | $291.77 Million | $147.35 Million |
Tourmaline Bio Inc. - Advanced Valuation Insights
This section examines the relationship between Tourmaline Bio Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.75 |
| Latest Market Cap to Assets Ratio | 3.99 |
| Asset Growth Rate (YoY) | 46.9% |
| Total Assets | $309.00 Million |
| Market Capitalization | $1.23 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Tourmaline Bio Inc.'s assets at a significant premium (3.99x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Tourmaline Bio Inc.'s assets grew by 46.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Tourmaline Bio Inc. (2019–2024)
The table below shows the annual total assets of Tourmaline Bio Inc. from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $309.00 Million | +46.94% |
| 2023-12-31 | $210.29 Million | +2211.44% |
| 2022-12-31 | $9.10 Million | -96.38% |
| 2021-12-31 | $251.42 Million | +64.57% |
| 2020-12-31 | $152.78 Million | +264.26% |
| 2019-12-31 | $41.94 Million | -- |
About Tourmaline Bio Inc.
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline c… Read more